M. Hizal Et Al. , "The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)," JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , 2022
Hizal, M. Et Al. 2022. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY .
Hizal, M., Bilgin, B., Paksoy, N., Atci, M. M., Kahraman, S., Kilickap, S., ... Guven, D. C.(2022). The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY .
Hizal, Mutlu Et Al. "The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)," JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , 2022
Hizal, Mutlu Et Al. "The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , 2022
Hizal, M. Et Al. (2022) . "The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY .
@article{article, author={Mutlu Hizal Et Al. }, title={The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)}, journal={JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY}, year=2022}